The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are
the primary treatments for ovarian cancer; however, patients often succumb to recurrence …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

The immunotherapeutic treatment of various cancers with an increasing number of immune
checkpoint inhibitors (ICIs) has profoundly improved the clinical management of advanced …

As cancer immunotherapy using immune checkpoint inhibitors (ICIs) is rapidly evolving in
clinical practice, it is necessary to identify biomarkers that will allow the selection of cancer …

Importance Hyperprogressive disease (HPD) is a recognized pattern of rapid tumor
progression during immune checkpoint inhibitor (ICI) treatment. Definitions of HPD have not …

The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …

Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different
types of tumors, leading to improvement in survival, even in patients with advanced cancers …

PD-L1/PD-1 blockade immunotherapy has significantly improved treatment outcome for
several cancer types compared to conventional cytotoxic therapies. However, the specific …

Many cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and
LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by …